Magentiq Eye’s artificial intelligence-aided software, Magentiq-Colo, has just received 510(k) approval from the FDA. The program is designed to assist clinicians in improving adenoma detection rates during colonoscopies by utilizing AI algorithms. The FDA approval follows a trial that included over 950 patients from several countries and established Magentiq-Colo as one of the highest-performing AI systems in the category. According to the business, using the software increased adenoma diagnosis by 26%, which might result in a 21% drop in colorectal cancer incidence and a 35% decrease in patient death. Following prior approvals in Europe and Israel, FDA approval will allow the business to commercialize the device in the United States. According to the founder of Magentiq Eye, this is only the beginning.

To know more: About the original article click here.